<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343262">
  <stage>Registered</stage>
  <submitdate>10/08/2011</submitdate>
  <approvaldate>10/08/2011</approvaldate>
  <actrnumber>ACTRN12611000846921</actrnumber>
  <trial_identification>
    <studytitle>The correlation of IL28B genotypes with patient demographics and disease characteristics in patients with Genotype 1 chronic hepatitis C</studytitle>
    <scientifictitle>The correlation of IL28B genotypes with patient demographics and disease characteristics in patients with Genotype 1 chronic hepatitis C</scientifictitle>
    <utrn>U1111-1123-2199</utrn>
    <trialacronym>Predict</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hepatitis C</healthcondition>
    <healthcondition>genotype 1</healthcondition>
    <healthcondition>antiviral treatment naive</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single blood sample taken for IL28B testing</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>National distribution of the IL28B genotypes for both the rs12979860 and rs8099917 SNPs.

Both SNPs will be tested through blood testing.</outcome>
      <timepoint>At the end of recruitment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To see if there is any correlation between the IL28B genotype and pre-treatment factors such as the extent of liver fibrosis, viral load and HCV genotype 1, Self reported ethnicity years of infection and fibrosis staging ,treatment initiation status post testing and 6 and 12 months post genotyping.
All the above parameters will be collected from patients and their medical records and entered into a database.</outcome>
      <timepoint>12 months after recruitment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>hepatitis C  (HCV)
genotype 1
evidence of hepatitis C infection for at least 6 months
Serological evidence of HCV infection by an anti-HCV antibody test (current or historical)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.  Infection with any HCV genotype other than genotype 1. Patients with indeterminate or mixed subtypes will be allowed.
2. Patients currently treated, or a history of having received any interferon or ribavirin based therapy or investigational anti-HCV agents at any previous time. 
3. Patients co-infected with hepatitis B, or HIV</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>2000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2000</postcode>
    <postcode>3000</postcode>
    <postcode>4000</postcode>
    <postcode>5000</postcode>
    <postcode>6000</postcode>
    <postcode>7000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australian Liver Association Clinical Trial Network</primarysponsorname>
    <primarysponsoraddress>GESA
PO Box 508
MULGRAVE 3170
VICTORIA</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche Products Pty Ltd</fundingname>
      <fundingaddress>4-10 Inman Road
Dee Why 
NSW, 2099</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, multicentre, single arm observational non-interventional investigator initiated study by members of the Australian Liver Association Clinical Trials Network.
This study will examine the distribution of the known IL28B polymorphisms (rs12979860 and rs8099917 SNPs) in patients with treatment naive genotype 1 chronic hepatitis C being considered for treatment in Australian clinics.
In addition to describing the IL28B distribution in the Australian cohort, we will investigate if there is any correlation between the IL28B genotype and pre-treatment factors such as the extent of liver fibrosis, viral load and HCV genotype 1 subtype.</summary>
    <trialwebsite>http://fmstorr.sydney.edu.au/fmi/iwp/res/iwp_home.html</trialwebsite>
    <publication>none as yet</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>WSLHN HUMAN RESEARCH ETHICS COMMITTEE</ethicname>
      <ethicaddress>(Westmead Campus)
Westmead Hospital
Westmead, 2145
NSW</ethicaddress>
      <ethicapprovaldate>16/12/2010</ethicapprovaldate>
      <hrec>HREC/10WMEAD/255HREC2010/12/4.18(3260)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>The Alfred
Commercial Road
Melbourne, 3004
Victoria</ethicaddress>
      <ethicapprovaldate>14/07/2011</ethicapprovaldate>
      <hrec>HREC/11/Alfred/23 (Local Reference: Project No 110/11)</hrec>
      <ethicsubmitdate>28/03/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Jacob George</name>
      <address>Storr Liver Unit
Westmead Hospital
Westmead
NSW, 2145</address>
      <phone>+ 61 2 9845 7705</phone>
      <fax />
      <email>jacob.george@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Jacob George</name>
      <address>Storr Liver Unit
Westmead Hospital
Westmead
NSW, 2145</address>
      <phone>+61 2 9845 7705</phone>
      <fax />
      <email>jacob.george@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jo Mitchell</name>
      <address>Gastroenterology Department
The Alfred
Commercial Road
Melbourne
Victoria
3004</address>
      <phone>+61 3 9076 2583</phone>
      <fax>+61 3 9076 2194</fax>
      <email>j.mitchell@alfred.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>